-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Uncertain potential clonal hematopoiesis (CHIP) refers to the presence of hematological malignant tumor-related mutations in the blood or bone marrow, but no other diagnostic criteria for hematological malignancies .
It is associated with an increased risk of cancer and is an inflammation-related disease
.
This phenomenon is common in people over 80 years old, but the impact of CHIP on people over 80 years old is unclear
diagnosis
The researchers screened for mutations in 1,794 elderly people over the age of 80 , and studied the correlation between CHIP and related pathologies
.
The incidence of common gene mutations in the health & anemia cohort
The incidence of common gene mutations in the health & anemia cohortThe results of the analysis showed that one-third of the elderly over the age of 80 have detected related mutations; and mutations are related to their reduced survival rate
.
JAK2 and splicing gene mutations, multiple mutations (DNMT3A, TET2 and ASXL1), and variant allele frequencies ≥0.
JAK2 and splicing gene mutations, multiple mutations (DNMT3A, TET2 and ASXL1), and variant allele frequencies ≥0.
The impact of the presence or absence of CHIP on the survival rate of subjects in the healthy & anemia cohort
The impact of the presence or absence of CHIP on the survival rate of subjects in the healthy & anemia cohortCombining mutation spectrum with abnormal red blood cell index can improve the reliability of bone marrow tumor prediction
.
On this basis, the researchers defined a predictive model that identified three risk groups with different probabilities of developing myeloid tumors
Combining mutation spectrum with abnormal red blood cell index can improve the reliability of bone marrow tumor prediction Combining mutation spectrum with abnormal red blood cell index can improve the reliability of bone marrow tumor prediction
Cumulative incidence of myeloid tumors in individuals in different risk groups
Cumulative incidence of myeloid tumors in individuals in different risk groupsDNMT3A, TET2, ASXL1 or JAK2 mutation and coronary heart disease and rheumatoid arthritis -related
.
Cytopenia is common in people 80 years and older, and the underlying cause is unknown in 30% of cases
Rheumatoid arthritis cytopenia is common in people 80 years and older, and the underlying cause is unknown in 30% of cases
Specific mutation patterns can stratify the risk of myeloid tumors and inflammation-related diseases in people over 80 years old.
Original source:
Marianna Rossi, et al.
Clinical relevance of clonal hematopoiesis in persons aged ≥80 years in this message
